Search

Establishment of Centre for Marine Therapeutics at Kolkata-Guwahati Cluster with NIPER-Kolkata as the nodal centre for Key Starting Materials KSM, Intermediates and Active Pharmaceutical Ingredients API.

Finding Novel Cost-effective Process and Formulation of RISDIPLAM to treat Spinal muscular atrophy SMA

The primary objective is to develop a cost-effective non-fringing synthetic route of Risdiplam, enhancing its efficacy and pharmacokinetic parameters. The RISDIPLAM synthesis is planned through a convergent process, involving the synthesis of Compoun

In silico discovery and biological evaluation of potential drug molecules to improve the treatment of Bedaquiline and Delamanid resistance in Mycobacterium tuberculosis.

Inherent stimuli triggered colloidal nanocarrier-based formulation for the management of ocular ailments and its pharmacokinetic investigation

Ocular drug delivery is crucial due to the growing global burden of visual ailments and the increasing aging population. Chronic ocular diseases often require prolonged administration, which is currently managed through invasive procedures like intra

Novel synthetic process and formulation development of ELIGLUSTAT tartrate.

Eliglustat, a glucosylceramide synthase inhibitor, is being developed for long-term treatment of adult patients with Gaucher disease type 1. Cerdelga, developed by Genzyme Corp, has been approved by the FDA in August 2014. Clinical studies show that

Novel vision based blister pack inspection for Pharmaceutical Industries

pH-Responsive Biodegradable Nanogels for Controlled and Targeted Drug Delivery Systems

Polymeric nanoparticles, particularly nanogels, have potential applications in biomedical and pharmaceutical fields, particularly in controlled drug delivery and diagnostics. These nanoparticles exhibit exceptional characteristics such as biodegradab

Preparation and Characterization of Novel Formulations of Nepafenac for the Management of Ocular Inflammation.

The project aims to improve drug delivery for postoperative pain and inflammation in cataract patients, addressing limitations of conventional therapies. It will develop a nanodispersion of Nepafenac, which will be incorporated into an in situ gel to

Process Development for Nusinersen: An Orphan Drug Used to Treat Spinal Muscular Atrophy (SMA)

Process Development of Risdiplam, Cladribine and Palovarotene Drugs for Rare/Orphan Diseases

Rare diseases are prevalent in a small number of populations and there is a deficit of medicines. In India, there is an existence of nearly 450 rare diseases, and it has become a challenge to treat these diseases due to poor diagnosis lack of proper